



Drug Name: Ibrance (palbociclib)
Date: 9-2018

Drug Name: Ibrance	
Required Medical Information:	<ul style="list-style-type: none"> • Prescriber is an oncologist • Drug is being used for a medically-accepted indication (approved by the FDA or compendia-supported) <ul style="list-style-type: none"> ○ Diagnosis of advanced or metastatic breast cancer <ul style="list-style-type: none"> ▪ Hormone receptor (HR)-positive breast cancer ▪ Human epidermal growth factor receptor 2 (HER2)-negative breast cancer ▪ Documentation of use: initial endocrine therapy or progression following endocrine therapy <ul style="list-style-type: none"> • If initial endocrine therapy: member is postmenopausal and drug will be used in combination with an aromatase inhibitor • If progression following endocrine therapy: drug will be used in combination with fulvestrant ○ Diagnosis of soft tissue sarcoma (retroperitoneal liposarcoma) <ul style="list-style-type: none"> ▪ Documented well-differentiated/dedifferentiated tumor
Quantity Limit:	21 capsules per 28 days
Coverage Duration:	12 months